IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer - PubMed
7 hours ago
- #immunotherapy
- #gynecological-cancer
- #NK-cells
- IL-15 enhances the efficacy of monoclonal antibody NEO-201 against endometrial and ovarian cancer.
- NEO-201 targets core 1 O-glycans on cancer cells and mediates killing via ADCC and CDC.
- Combining NEO-201 with IL-15 boosts NK cell activity, improving ADCC in vitro.
- The combination modestly prolonged survival in mice with ovarian cancer.
- Future potential includes combining NEO-201 and IL-15 with CAR-NK cell therapy.